Lung cancer signatures in plasma based on proteome profiling of mouse tumor models.
暂无分享,去创建一个
Kwon-Sik Park | Vitor M Faça | Christopher J Kemp | Sharon J Pitteri | Gary Goodman | Raju Kucherlapati | Julien Sage | Qing Zhang | S. Hanash | H. Varmus | R. Kucherlapati | R. DePinho | A. Gazdar | J. Sage | Kwon-Sik Park | K. Politi | W. Lockwood | Chee-Hong Wong | C. Kemp | G. Goodman | Alice Chin | A. Taguchi | V. Faça | S. Pitteri | K. Kelly-Spratt | Qing Zhang | D. Dinulescu | William W Lockwood | Adi F Gazdar | Daniela M Dinulescu | Alice Chin | Ronald A Depinho | Chee-Hong Wong | Samir M Hanash | Katerina Politi | Ayumu Taguchi | Sharon J. Pitteri | Harold E Varmus | Karen Kelly-Spratt | Chee‐Hong Wong
[1] Jacob J. Kennedy,et al. Tumor microenvironment-derived proteins dominate the plasma proteome response during breast cancer induction and progression. , 2011, Cancer research.
[2] Jacob Kennedy,et al. Plasma Proteome Profiles Associated with Inflammation, Angiogenesis, and Cancer , 2011, PloS one.
[3] Gerald C. Chu,et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression , 2011, Nature.
[4] W. Berger,et al. Dual inhibition of EGFR and mTOR pathways in small cell lung cancer , 2010, British Journal of Cancer.
[5] A. Sweet-Cordero,et al. Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma. , 2010, Cancer research.
[6] P. Rouanet,et al. Serum protein signature may improve detection of ductal carcinoma in situ of the breast , 2010, Oncogene.
[7] Liese C C Pruitt,et al. Integrated Proteomic Analysis of Human Cancer Cells and Plasma from Tumor Bearing Mice for Ovarian Cancer Biomarker Discovery , 2009, PloS one.
[8] D. Feldser,et al. Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma , 2009, Nature.
[9] S. Richard,et al. Identification of a Sam68 Ribonucleoprotein Complex Regulated by Epidermal Growth Factor* , 2009, The Journal of Biological Chemistry.
[10] L. Hood,et al. Deep depletion of abundant serum proteins reveals low‐abundant proteins as potential biomarkers for human ovarian cancer , 2009, Proteomics. Clinical applications.
[11] R. Lewensohn,et al. Use of narrow‐range peptide IEF to improve detection of lung adenocarcinoma markers in plasma and pleural effusion , 2009, Proteomics.
[12] S. Lam,et al. Connective tissue-activating peptide III: a novel blood biomarker for early lung cancer detection. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Caicun Zhou,et al. Clinicopathological features and epidermal growth factor receptor mutations associated with epithelial–mesenchymal transition in non‐small cell lung cancer , 2009, Respirology.
[14] Claude C. Warzecha,et al. ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. , 2009, Molecular cell.
[15] S. Hanash,et al. Comprehensive Proteome Analysis of an Apc Mouse Model Uncovers Proteins Associated with Intestinal Tumorigenesis , 2009, Cancer Prevention Research.
[16] S. Hanash,et al. In-depth proteomics to define the cell surface and secretome of ovarian cancer cells and processes of protein shedding. , 2009, Cancer research.
[17] S. Hanash,et al. Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] J. Pérez-Gil,et al. Structure of pulmonary surfactant membranes and films: the role of proteins and lipid-protein interactions. , 2008, Biochimica et biophysica acta.
[19] S. Hanash,et al. Proteomic Analysis of Ovarian Cancer Cells Reveals Dynamic Processes of Protein Secretion and Shedding of Extra-Cellular Domains , 2008, PloS one.
[20] Michelle A. Anderson,et al. A Mouse to Human Search for Plasma Proteome Changes Associated with Pancreatic Tumor Development , 2008, PLoS medicine.
[21] S. Hanash,et al. Plasma proteome profiling of a mouse model of breast cancer identifies a set of up-regulated proteins in common with human breast cancer cells. , 2008, Journal of proteome research.
[22] Derek Y. Chiang,et al. Characterizing the cancer genome in lung adenocarcinoma , 2007, Nature.
[23] W. Gerald,et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. , 2007, The Journal of clinical investigation.
[24] Veronika A. Glukhova,et al. Contribution of protein fractionation to depth of analysis of the serum and plasma proteomes. , 2007, Journal of proteome research.
[25] Y. Yatabe,et al. Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. , 2007, Cancer research.
[26] M. Páez de la Cadena,et al. Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma , 2007, British Journal of Cancer.
[27] M. Mann,et al. A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC) , 2006, Nature Protocols.
[28] J. Crowley,et al. Bortezomib (PS-341) in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group Phase II Trial (S0327) , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[29] Brendan MacLean,et al. General framework for developing and evaluating database scoring algorithms using the TANDEM search engine , 2006, Bioinform..
[30] Veronika A. Glukhova,et al. Quantitative analysis of acrylamide labeled serum proteins by LC-MS/MS. , 2006, Journal of proteome research.
[31] H. Varmus,et al. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. , 2006, Genes & development.
[32] H. Frierson,et al. Comprehensive analysis of HE4 expression in normal and malignant human tissues , 2006, Modern Pathology.
[33] Ewa Wójcik,et al. Pretreatment Serum Levels of Cytokines and Cytokine Receptors in Patients with Non-Small Cell Lung Cancer, and Correlations with Clinicopathological Features and Prognosis , 2006, Oncology.
[34] S. Cross,et al. WFDC2 (HE4): A potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung , 2006, Respiratory research.
[35] Jeffrey T. Chang,et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.
[36] B. de Strooper,et al. ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[37] G. Omenn,et al. The Beta-Carotene and Retinol Efficacy Trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping beta-carotene and retinol supplements. , 2004, Journal of the National Cancer Institute.
[38] G. Millat,et al. Structure and function of the NPC2 protein. , 2004, Biochimica et biophysica acta.
[39] E. Birney,et al. The International Protein Index: An integrated database for proteomics experiments , 2004, Proteomics.
[40] Robertson Craig,et al. TANDEM: matching proteins with tandem mass spectra. , 2004, Bioinformatics.
[41] J. Yates,et al. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. , 2004, Analytical chemistry.
[42] T. Yanagida,et al. Engagement of CD44 Promotes Rac Activation and CD44 Cleavage during Tumor Cell Migration* , 2004, Journal of Biological Chemistry.
[43] H. Samaratunga,et al. Expression of the Disintegrin Metalloprotease, ADAM-10, in Prostate Cancer and Its Regulation by Dihydrotestosterone, Insulin-Like Growth Factor I, and Epidermal Growth Factor in the Prostate Cancer Cell Model LNCaP , 2004, Clinical Cancer Research.
[44] A. Berns,et al. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. , 2003, Cancer cell.
[45] R. Aebersold,et al. A statistical model for identifying proteins by tandem mass spectrometry. , 2003, Analytical chemistry.
[46] S. Duan,et al. Induction of tumor angiogenesis by Slit-Robo signaling and inhibition of cancer growth by blocking Robo activity. , 2003, Cancer cell.
[47] Michèl Schummer,et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. , 2003, Cancer research.
[48] Rolf Apweiler,et al. Faculty Opinions recommendation of Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. , 2003 .
[49] Mitchell D Schnall,et al. Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. , 2002, Cancer cell.
[50] Alexey I Nesvizhskii,et al. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. , 2002, Analytical chemistry.
[51] Z. Werb,et al. The metalloprotease Kuzbanian (ADAM10) mediates the transactivation of EGF receptor by G protein–coupled receptors , 2002, The Journal of cell biology.
[52] G. Camenisch,et al. ANGPTL3 Stimulates Endothelial Cell Adhesion and Migration via Integrin αvβ3 and Induces Blood Vessel Formation in Vivo * , 2002, The Journal of Biological Chemistry.
[53] T. Fujiwara,et al. Angptl3 regulates lipid metabolism in mice , 2002, Nature Genetics.
[54] H. Varmus,et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. , 2001, Genes & development.
[55] T. Rabbitts,et al. Inadequate lung development and bronchial hyperplasia in mice with a targeted deletion in the Dutt1/Robo1 gene , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[56] P. Herrlich,et al. Regulation of alternative pre‐mRNA splicing by the ERK MAP‐kinase pathway , 2001, The EMBO journal.
[57] D. Botstein,et al. Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[58] S. Infusino,et al. Serum concentrations of proinflammatory cytokines in advanced non small cell lung cancer patients. , 1998, Journal of experimental & clinical cancer research : CR.
[59] J. Roth,et al. Ki‐ras and p53 mutations are early and late events, respectively, in urethane‐induced pulmonary carcinogenesis in A/J mice , 1996, Molecular carcinogenesis.
[60] J. Ben-Ezra,et al. Small cell carcinomas of the lung express the Bcl-2 protein. , 1994, The American journal of pathology.
[61] Charles Darwin,et al. Experiments , 1800, The Medical and physical journal.
[62] Rob J. van Klaveren,et al. Screening and Early Detection of Lung Cancer , 2011, Cancer journal.
[63] Adam Rauch,et al. Computational Proteomics Analysis System (CPAS): an extensible, open-source analytic system for evaluating and publishing proteomic data and high throughput biological experiments. , 2006, Journal of proteome research.
[64] T. Jacks,et al. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer , 2005, Nature Medicine.
[65] P. Herrlich,et al. CD44: From adhesion molecules to signalling regulators , 2003, Nature Reviews Molecular Cell Biology.
[66] G. Pelosi,et al. Detection of the neural cell adhesion molecule (NCAM) in serum of patients with small‐cell lung cancer (SCLC) with “limited” or “extensive” disease, and bone‐marrow infiltration , 1994, International journal of cancer. Supplement = Journal international du cancer. Supplement.
[67] A. Vangsted,et al. New serum markers for small-cell lung cancer. II. The neural cell adhesion molecule, NCAM. , 1994, Cancer detection and prevention.